TAE Life Sciences’ latest research demonstrates the potential of next-generation BNCT to combine targeted radiation with immune activation for improved cancer treatment outcomes.
Immuno-oncology Combination | 11/04/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy